Memantine effect on patients with schizophrenia

Effects of Memantine on cognitive impairment in schizophrenic patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190606043827N1

Enrollment

Registered

2020-02-08

Start date

2019-09-01

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: The group was treated with memantine 5 mg (Made in Iran and Tolid daru factory)daily for 3 months and dosed at a maximum of 20 mg daily. This dose was selected acco

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Schizophrenia according to DSM-IV criteria Age 18 to 50 years Receiving common drugs for schizophrenia for at least 3 months before the start of the study (Patients within 3 months of the previous 3 month antipsychotic with a constant dose of 300 to 1000 mg of chlorpromazine (except for clozapine) and a fixed dose of anticholinergic drug of 4 to 8 mg TG Phenidyl) Mental Status Mini Test Score (MMSE) Between 18 and 24

Exclusion criteria

Exclusion criteria: Dependence and drug addiction smoking History of trauma to the head History of seizure Severe liver and kidney function disorders Severe neurological disorders Depression Receiving drugs that affect cognitive symptoms

Design outcomes

Primary

Measure	Time frame
Grade Severity of Positive and Negative Symptoms of Schizophrenia. Timepoint: Measure the mean score of severity of positive and negative symptoms of schizophrenia from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Questionnaire on the severity of positive and negative symptoms of schizophrenia.;Hamilton Depression Scale Score. Timepoint: Measurement of mean Hamilton Depression Rating Scale from baseline, 6th and 12th week after drug and placebo study. Method of measurement: Hamilton Depression Scale Questionnaire.;Adult Wechsler Memory Test Score. Timepoint: Measurement of mean Wechsler Adult Memory Test score from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Adult Wechsler memory test.	—

Measure

Time frame

Grade Severity of Positive and Negative Symptoms of Schizophrenia. Timepoint: Measure the mean score of severity of positive and negative symptoms of schizophrenia from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Questionnaire on the severity of positive and negative symptoms of schizophrenia.;Hamilton Depression Scale Score. Timepoint: Measurement of mean Hamilton Depression Rating Scale from baseline, 6th and 12th week after drug and placebo study. Method of measurement: Hamilton Depression Scale Questionnaire.;Adult Wechsler Memory Test Score. Timepoint: Measurement of mean Wechsler Adult Memory Test score from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Adult Wechsler memory test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ahmad Hosseini

Kashan University of Medical Sciences

hosseini-sah@Kaums.ac.ir+98 31 5550 0111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026